DelistingOct 6, 2026, 04:07 PM
Kyntra Bio Faces Nasdaq Delisting; Seeks Hearing
AI Summary
Kyntra Bio, Inc. received a delisting determination from Nasdaq for failing to meet listing rule 5450(b). The company has requested a hearing to appeal this decision and seek additional time to regain compliance. Trading of its common stock will continue on the Nasdaq Global Select Market pending the outcome of the hearing.
Key Highlights
- Kyntra Bio received a determination letter from Nasdaq for delisting its common stock from the Nasdaq Global Select Market.
- The company failed to demonstrate compliance with Nasdaq Listing Rule 5450(b) by the September 29, 2026 deadline.
- Kyntra Bio has requested a hearing before a Nasdaq Hearings Panel to review the delisting determination.
- The hearing request stays the suspension of securities pending the Panel's decision, allowing trading to continue under 'KYNB'.
- The company is preparing a compliance plan to regain compliance with Nasdaq's continued listing requirements.
Price Impact
More from KYNB